Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $50,250.00 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Francis Lo sold 3,125 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $16.08, for a total transaction of $50,250.00. Following the transaction, the insider owned 315,978 shares of the company’s stock, valued at approximately $5,080,926.24. This represents a 0.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Francis Lo also recently made the following trade(s):

• On Monday, December 22nd, Francis Lo sold 4,394 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $17.50, for a total transaction of $76,895.00.
• On Monday, December 15th, Francis Lo sold 113,890 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.57, for a total transaction of $1,773,267.30.

Adaptive Biotechnologies Stock Down 0.4%

Adaptive Biotechnologies stock traded down $0.06 during mid-day trading on Tuesday, hitting $16.11. 3,352,268 shares of the company’s stock were exchanged, compared to its average volume of 2,104,911. The company’s 50 day simple moving average is $16.50 and its 200-day simple moving average is $14.22. The firm has a market capitalization of $2.46 billion, a P/E ratio of -29.83 and a beta of 2.18. Adaptive Biotechnologies Corporation has a fifty-two week low of $5.97 and a fifty-two week high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its earnings results on Wednesday, November 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. Adaptive Biotechnologies had a negative return on equity of 58.40% and a negative net margin of 31.50%.The firm had revenue of $93.97 million during the quarter, compared to analysts’ expectations of $58.76 million. During the same period in the previous year, the firm earned ($0.22) earnings per share. The company’s revenue was up 102.4% on a year-over-year basis. Research analysts expect that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have commented on ADPT shares. Wall Street Zen upgraded shares of Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Morgan Stanley started coverage on shares of Adaptive Biotechnologies in a research report on Monday, December 1st. They issued an “equal weight” rating and a $21.00 price objective on the stock. Piper Sandler increased their price objective on Adaptive Biotechnologies from $15.00 to $20.00 and gave the company an “overweight” rating in a report on Wednesday, October 15th. BTIG Research boosted their target price on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, October 8th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.11.

Hedge Funds Weigh In On Adaptive Biotechnologies

Several institutional investors and hedge funds have recently made changes to their positions in the business. Ameriprise Financial Inc. lifted its stake in Adaptive Biotechnologies by 84.3% in the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after purchasing an additional 2,731,648 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in shares of Adaptive Biotechnologies by 544.0% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock valued at $36,523,000 after acquiring an additional 2,062,282 shares during the last quarter. Summit Partners Public Asset Management LLC purchased a new stake in Adaptive Biotechnologies during the 3rd quarter valued at about $14,934,000. First Trust Advisors LP boosted its holdings in Adaptive Biotechnologies by 4,802.2% during the 2nd quarter. First Trust Advisors LP now owns 741,306 shares of the company’s stock valued at $8,636,000 after acquiring an additional 726,184 shares during the period. Finally, Peregrine Capital Management LLC bought a new position in Adaptive Biotechnologies during the 2nd quarter worth approximately $8,187,000. Institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.